Teva recalls 15mg Lansoprazole tablets due to subpotent drug
Teva Pharmaceuticals USA recalls 15mg Lansoprazole Delayed-Release Orally Disintegrating Tablets (NDC 0093-3008-93) for subpotent drug content. This medication may not provide the intended treatment.
Lower-risk recall
Subpotent Drug.
Contact the company
What happened, in plain English
Teva Pharmaceuticals USA is recalling 15mg Lansoprazole Delayed-Release Orally Disintegrating Tablets because they contain less active ingredient than intended. This means the medication may not work as prescribed for conditions like acid reflux. Read more at govinfonow.com/recall/39117-teva-recalls-15mg-lansoprazole-tablets-due-to-subpotent-drug.
Source Summary by GovInfoNow · govinfonow.com/recall/39117-teva-recalls-15mg-lansoprazole-tablets-due-to-subpotent-drug · Updated October 5, 2026 · FDA enforcement record: FDA #D-1006-2019
Cite this page
“Teva recalls 15mg Lansoprazole tablets due to subpotent drug.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/39117-teva-recalls-15mg-lansoprazole-tablets-due-to-subpotent-drug. Based on FDA recall #D-1006-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1006-2019%22&limit=1).
Why it’s dangerous
The tablets contain less active drug than labeled, so they may not effectively treat acid-related conditions. This subpotency could lead to inadequate symptom management if the medication is not working properly.
Who’s affected
People who have the recalled 15mg Lansoprazole tablets (NDC 0093-3008-93) from Teva Pharmaceuticals USA. Those with acid reflux or ulcers who need this medication are most at risk.
How to tell if you have this one
Check for the product name 'Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg' with 100 tablets in 10 blister cards. The NDC code is 0093-3008-93 and it was manufactured in Israel with lot number 25Q002 (expired 11/2019).
- Brand
Teva- Category
Drug
What to do — step by step
Check Product Details
Verify the product name, NDC code, and lot number to confirm if it matches the recalled items.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the United States.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 8 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
What should I do if I have the recalled tablets?
Check the product details to confirm if it matches the recalled items. If it does, stop using it and contact your doctor.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1006-2019 (March 11, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1006-2019 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.